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Abstract 
Background 
Few studies have investigated the risk of adverse outcomes in older people with renal 
impairment presenting to primary care with a urinary tract infection (UTI). The aim of 
this study was to determine the risk of adverse outcomes in patients aged ≥65 years 
presenting to primary care with a UTI, by estimated glomerular filtration rate (eGFR) 
and empirical prescription of nitrofurantoin versus trimethoprim. 
Methods and Findings 
This was a retrospective cohort study using linked health record data from 795,484 
patients from 393 general practices in England, who were aged ≥65 years between 
2010 and 2016. Patients were entered into the cohort if they presented with a UTI and 
had a creatinine measurement in the 24 months prior to presentation. We calculated 
an eGFR to estimate risk of adverse outcomes by renal function, and propensity-score 
matched patients with eGFRs <60mls/min/1.73m2 to estimate risk of adverse 
outcomes between those prescribed trimethoprim and nitrofurantoin. Outcomes were 
14-day risk of re-consultation for urinary symptoms and same-day antibiotic 
prescription (proxy for treatment non-response), hospitalisation for UTI, sepsis, or 
acute kidney injury (AKI), and 28-day risk of death. 
Of 123,607 eligible patients with a UTI, we calculated an eGFR for 116,945 (95%). 
Median age was 76 (IQR, 70-83) years and 32,428 (28%) were male. Compared to an 
eGFR of >60mls/min/1.73m2,  patients with an eGFR of <60mls/min/1.73m2 had 
greater odds of hospitalisation for UTI (adjusted ORs ranged from 1.14, (95% CI 1.01-
1.28, p=0.028) for eGFRs of 45-59, to 1.68 (95% CI 1.01-2.82, p<0.001) for 
eGFRs<15), and AKI (adjusted ORs ranged from 1.57, (95% CI 1.29-1.91, p<0.001) 
for eGFRs of 45-59, to 4.53 (95% CI 2.52-8.17, p<0.001) for eGFRs<15).  Compared 
to an eGFR of >60mls/min/1.73m2, patients with an eGFR of <45 had significantly 
greater odds of hospitalisation for sepsis, and those with an eGFR <30 had 
significantly greater odds of death. Compared to trimethoprim, nitrofurantoin 
prescribing was associated with lower odds of hospitalisation for AKI (ORs ranged 
from 0.62, (95% CI 0.40-0.94, p=0.025) for eGFRs of 45-59 to 0.45 (95% CI 0.25-0.81, 
p=0.008) for eGFRs <30). Nitrofurantoin was not associated with greater odds of any 
adverse outcome. Our study lacked data on urine microbiology and antibiotic-related 
adverse events. Despite our design, residual confounding may still have affected some 
of our findings. 
Conclusions  
Older patients with renal impairment presenting to primary care with a UTI had an 
increased risk of UTI-related hospitalisation and death, suggesting a need for 
interventions that reduce the risk of these adverse outcomes. Nitrofurantoin 
prescribing was not associated with an increased risk of adverse outcomes in patients 
with an eGFR <60mls/min/1.73m2 and could be used more widely in this population.  
 
 
 
 
 
 
 
Author Summary 
Why was this study done? 
 It is not known if older adults with impaired kidney function are at increased risk 
of hospitalisation or death following a urinary tract infection (UTI). 
 Nitrofurantoin is an antibiotic used to treat UTI but is not recommended in 
people with impaired kidney function. However, the evidence supporting this 
recommendation is limited. 
What did the researchers do and find? 
 This study used linked health record data from general practices and hospitals 
in England and estimated risk of hospitalisation and death for older adults with 
impaired kidney function presenting to primary care with a suspected UTI. 
 Older adults with impaired kidney function had greater risk of a UTI-related 
hospitalisation and death in the 14-28 days following a UTI. 
 Older adults with impaired kidney function who were treated with nitrofurantoin 
were not at greater risk of an adverse outcome, and were less likely to 
experience a hospital admission for worsening kidney function. 
What do these findings mean? 
 There is a need for strategies that prevent UTIs and reduce the risk of UTI-
related hospitalisations and death in older adults with impaired kidney function. 
 Nitrofurantoin was not associated with worse outcomes and could be used 
more widely in this population. 
 
Introduction 
The Kidney Disease Improving Global Outcomes working group define degrees of 
renal impairment using the glomerular filtration rate (GFR)[1]. GFRs 
<60mls/min/1.73m2 are split into four groups and reflect worsening renal function, from 
mild impairment to renal failure. Around 6% of adults in the UK have an estimated 
glomerular filtration rate (eGFR) of <60ml/min/1.73m2[2]. This increases with age to 
around 20% of those aged ≥65. There is increasing evidence of an association 
between renal impairment and infection[3-6]. Oxidative stress in renal impairment 
disrupts the function of inflammatory cytokines, and may impair immune response 
during an infection[7]. In more severe renal impairment, uremic toxins impair the 
function of T-lymphocyte and antigen-presenting cells, which play important roles in 
cellular and humoral immunity[8]. Despite the high prevalence in older adults, and the 
association with infection, few studies have investigated outcomes following an 
infectious illness in older people with renal impairment. 
A cohort study in UK primary care showed around 20% of adults aged 65 and over 
had at least one UTI over a median follow-up of five years[9]. Most adults presenting 
to primary care with symptoms and signs of a UTI receive empirical antibiotics at the 
same consultation, without knowledge of microbiological findings or antibiotic 
susceptibilities[10]. Nitrofurantoin and trimethoprim (alone or with sulfamethoxazole) 
are the two most commonly prescribed antibiotics for empirical treatment of UTIs and 
are recommended by clinical guidelines in the UK, USA, and Europe[11,12]. 
Nitrofurantoin use was initially limited to those with an eGFR ≥60mls/min/1.73m2, due 
to concerns about poorer efficacy in patients with lower eGFRs. In 2014, a review of 
the evidence[13] and a retrospective cohort study[14] prompted the UK Medicines and 
Healthcare products Regulation Authority to lower the threshold for nitrofurantoin use 
to an eGFR≥45 mls/min/1.73m2. However, outcomes following empirical nitrofurantoin 
prescribing in older adults with a UTI and an eGFR <60 mls/min/1.73m2 are yet to be 
fully evaluated. There are also concerns about trimethoprim use in older adults with 
renal impairment, with increasing evidence of an association with hyperkalaemia and 
sudden death, especially when prescribed to patients already taking angiotensin-
converting enzyme inhibitors, angiotensin-II receptor blockers, or potassium-sparing 
diuretics[15-19]. 
We used data from anonymised linked health records to estimate the risk of adverse 
outcomes in older patients with renal impairment empirically treated for suspected UTI 
in primary care. We firstly compared outcomes by eGFR, to understand whether 
severity of renal impairment was associated with risk of adverse outcome following a 
UTI. This would help identify which patients would most benefit from interventions that 
improved prevention and/or treatment of UTI. We also compared outcomes for older 
patients with an eGFR<60 mls/min/1.73m2 who were prescribed empirical 
nitrofurantoin versus empirical trimethoprim to inform prescribing decisions and 
explore if nitrofurantoin prescribing is safe in patients with renal impairment. 
 
Methods 
Data Source 
We used the Clinical Practice Research Datalink (CPRD), an electronic database of 
anonymised primary care records, covering 11.3 million patients from 674 general 
practices across the UK[20]. Approximately 7% of the UK population are included and 
patients are broadly representative of the wider UK population in terms of age, sex 
and ethnicity. The CPRD holds data on demographics, clinical encounters and 
diagnoses (coded using Read codes), drug prescriptions, laboratory tests and referrals 
to specialists. Data are available once they have met a series of quality checks on 
completeness and reliability and the CPRD deems them to be of the standard required 
for research purposes. Linked hospital and death registration data is available for 
patients from approximately 50% of contributing English practices. Hospital diagnoses 
and causes of death are recorded using version 10 of the International Classification 
of Disease (ICD-10). 
The CPRD Independent Scientific Advisory Committee approved the study protocol 
and analysis plan (protocol number 17_250, S1 Protocol). Further ethical approval 
was not required as the proposed research was within the remit of the CPRD’s broad 
National Research Ethics Service approval. We used the Reporting of Studies 
Conducted using Observational Routinely-collected Health Data (RECORD) 
statement and checklist (S1 RECORD Checklist) to guide study reporting[21].  
Design and participants 
This was a retrospective cohort study using linked health record data. Patients were 
eligible for inclusion if, between 1st January 2010 and 31st December 2016, their data 
were of the quality required by CPRD, they were ≥65 years old and eligible for data-
linkage. Only patients registered with practices that had consented to data-linkage 
would have linked hospital and death registry data. We excluded patients if they were 
temporary residents (i.e., they registered with the practice for an acute problem but 
this was not their normal “long-term” practice and thus medical record data would be 
limited) or had periods during their registration with the practice where CPRD was 
unable to collect data, potentially leading to incomplete exposure/event capture. We 
identified eligible patients with a Read code indicating an incident primary care 
presentation with a suspected UTI (codes available in S1 Appendix), a prescription 
code indicating same-day empirical prescribing of a relevant antibiotic, and a 
creatinine record in the preceding 24 months. We defined ‘incident’ as a presentation 
without a previous consultation with a UTI-related Read code, or trimethoprim or 
nitrofurantoin prescription in the preceding 90 days. We used the first incident episode 
during each patient’s follow-up period. We excluded UTI episodes with a hospital 
discharge in the preceding 14 days to exclude hospital-acquired infections.   
Exposures 
We used the most recent serum creatinine value recorded in the 24 months preceding 
the incident UTI and data for patient age, gender and ethnicity to calculate an eGFR 
as per the Modification of Diet in Renal Disease (MDRD) Study equation[22]. We 
categorised eGFRs as ≥60mls/min/1.73m2, 45-59mls/min/1.73m2, 30-
44mls/min/1.73m2, 15-29mls/min/1.73m2, and <15mls/min/1.73m2. These categories 
are similar to those used by the UK National Institute of Health and Care Excellence 
to categorise the stages of chronic kidney disease except we combined eGFRs of 60-
89mls/min/1.73m2 with those ≥90 mls/min/1.73m2. This was because eGFRs 
≥60mls/min/1.73m2 without additional evidence of kidney damage are clinically 
regarded as normal, and previous research found no difference in infection incidence 
or outcome between these two groups[5]. We used those with an eGFR 
≥60mls/min/1.73m2 as the reference and compared rates of adverse outcomes against 
the four other eGFR categories. We used the recorded empirical antibiotic prescription 
as the exposure variable to compare risk of adverse outcomes between patients with 
eGFRs <60mls/min/1.73m2 prescribed trimethoprim versus nitrofurantoin. 
Outcomes 
We assessed the impact of our stated exposures on the following adverse outcomes 
for patients empirically treated in primary care for an incident suspected UTI: 
1. Re-consultation for urinary symptoms and a same-day antibiotic prescription 
within 14 days following the incident UTI, as a proxy for treatment non-
response, ascertained through Read and prescription codes recorded in 
primary care records. 
2. Hospitalisation for UTI, sepsis, or acute kidney injury (AKI) within 14 days 
following the incident UTI ascertained from ICD-10 codes recorded in linked 
hospital admission data for the first episode of a hospital admission, i.e., the 
episode most likely responsible for the admission. 
3. Death within 28 days following the incident UTI using linked death registration 
data. 
We also initially planned to include hospitalisation for pyelonephritis as an 
outcome. However, our exploratory work showed that pyelonephritis was rarely 
coded in hospital records (only 8 events in total) and thus was unlikely to be a 
reliable outcome for use with these data. 
Statistical Analyses 
We used primary care demographic and clinical codes to describe baseline 
characteristics for patients by exposure status. To assess the impact of eGFR, we 
compared rates of each outcome in those with an eGFR ≥60mls/min/1.73m2 to those 
in each category related to an eGFR<60mls/min/1.73m2, and used logistic regression 
to estimate odds ratios (OR) and 95% confidence intervals (CI). We adjusted for 
potential confounders of the association between renal impairment and outcome, 
including age, Index of Multiple Deprivation score quintile, Charlson comorbidity 
score[23],  the presence or absence of a record indicating diabetes, dementia, 
coronary heart disease, stroke, cancer, and heart failure, and polypharmacy. We 
inferred the presence of polypharmacy if the patient’s record showed repeated monthly 
prescribing of ≥5 medications in the year prior to the incident UTI. We also adjusted 
for the choice and duration of antibiotic therapy used to treat the incident UTI. 
To assess the impact of empirical trimethoprim versus nitrofurantoin prescribing, we 
used a range of demographic and clinical variables to match patients on their 
propensity to receive a trimethoprim prescription. These included the confounders 
listed above and presence or absence of a record indicating urinary incontinence or 
long-term catheterisation, and long-term prescribing of angiotensin-converting 
enzyme inhibitors, angiotensin-II receptor blockers, or potassium-sparing diuretics. 
We used nearest neighbour matching with no replacement and matched each patient 
with a nitrofurantoin prescription to three patients with trimethoprim prescriptions. We 
assessed balance in measured baseline covariates between matched groups by 
visually inspecting jitter plots and histograms of covariate distribution before and after 
matching, and by calculating standardised mean differences for covariates between 
groups. We regarded standardised mean differences of <0.1 as reflecting adequate 
balance[24,25]. We used mixed effects logistic regression to account for clustering by 
general practice and calculated ORs and 95% CIs for each outcome.  
All statistical tests were 2-sided with p<0.05 considered statistically significant but an 
effect size of 10% considered clinically significant. P-values were derived using two-
tailed Wald tests. Analyses were conducted in R version 3.2.1. 
 
Results 
From a cohort of 795,484 patients aged 65 and over, we identified 123,607 with an 
incident UTI empirically treated with a relevant antibiotic (Fig 1). Of these, 116,945 
(95%) patients had a creatinine measurement recorded in the 24 months prior to the 
incident UTI. In this final cohort, 32,428 (28%) were male and the median age at time 
of incident UTI was 76 years (IQR 70-83). Almost one third of creatinine 
measurements were in the 90 days prior to the incident UTI. Median duration between 
most recent creatinine and UTI was 169 days (IQR 65-285). Using the MDRD study 
equation, 76,112 (65.1%) of patients were assigned an eGFR ≥60, 26,970 (23.1%) an 
eGFR of 45-59, 10,854 (9.3%) an eGFR of 30-44, 2667 (2.3%) an eGFR of 15-29, and 
342 (0.3%) an eGFR of <15. Baseline characteristics showed that patients with lower 
eGFRs had a relatively greater number of comorbidities and comprised greater 
proportions of patients with polypharmacy (Table 1). Trimethoprim was the most 
commonly prescribed empirical antibiotic across all eGFR groups. Nitrofurantoin was 
the second most common except in patients with an eGFR <15mls/min/1.73m2.   
 
Fig 1. Flow of patients from initial identification in the database through to final 
cohort. 
  
Table 1. Baseline characteristics of included patients according to eGFR category.  
 
eGFR ≥60 eGFR 45-59 eGFR 30-44 eGFR 15-29 eGFR <15 
N 76112 (65.1) 26970 (23.1) 10854 (9.3) 2667 (2.3) 342 (0.3) 
Men 21816 (28.7) 6674 (24.7) 2894 (26.7) 880 (33.0) 164 (48.0) 
Mean (SD) age 75.2 (7.9) 79.1 (8.3) 82.5 (8.0) 83.2 (8.0) 79 (8.2) 
Prescribed antibiotic 
Amoxicillin 
Cefalexin 
Ciprofloxacin 
Co-amoxiclav 
Nitrofurantoin 
Trimethoprim 
 
3370 (4.4) 
4168 (5.5) 
2344 (3.1) 
3170 (4.2) 
16719 (22.0) 
46341 (60.9) 
 
1367 (5.1) 
1749 (6.5) 
811 (3.0) 
1227 (4.5) 
5237 (19.4) 
16579 (61.5) 
 
680 (6.3) 
917 (8.4) 
388 (3.6) 
613 (5.6) 
1815 (16.7) 
6441 (59.3) 
 
289 (10.8) 
319 (12.0) 
148 (5.5) 
208 (7.8) 
391 (14.7) 
1312 (49.2) 
 
45 (13.2) 
47 (13.7) 
26 (7.6) 
44 (12.9) 
41 (12.0) 
139 (40.6) 
Index of multiple deprivation decile 
1 or 2 (least deprived) 
3 or 4 
5 or 6 
7 or 8 
9 or 10 (most deprived) 
 
19939 (26.2) 
18413 (24.2) 
16606 (21.8) 
12283 (16.1) 
8871 (11.7) 
 
6401 (23.7) 
6524 (24.2) 
5859 (21.7) 
4626 (17.2) 
3560 (13.2) 
 
2292 (21.1) 
2526 (23.3) 
2443 (22.5) 
1918 (17.7) 
1675 (15.4) 
 
560 (21.0) 
619 (23.2) 
615 (23.1) 
477 (17.9) 
396 (14.8) 
 
65 (19.0) 
77 (22.5) 
85 (24.9) 
45 (13.2) 
70 (20.5) 
Housebound 2261 (3.0) 1201 (4.5) 866 (8.0) 267 (10.0) 34 (9.9) 
Respiratory disease 15853 (20.8) 5521 (20.5) 2208 (20.3) 538 (20.2) 46 (13.5) 
Cardiac failure 2187 (2.9) 1733 (6.4) 1367 (12.6) 499 (18.7) 56 (16.4) 
Dementia 3724 (4.9) 2024 (7.5) 1129 (10.4) 265 (9.9) 21 (6.1) 
Peripheral vascular disease 2903 (3.8) 1502 (5.6) 953 (8.8) 319 (12.0) 43 (12.6) 
795,484 patients ≥65 years old between 1st January 2010 and 31st December 2016 
with data of the required quality and eligible for data linkage. 
769,574 patients eligible for inclusion 
123,607 patients had a record indicating an empirically treated UTI 
116,945 patients in the final cohort 
Patients with no record of a creatinine measurement in the 
prior 2 years (6662) 
Patients with temporary registrations or gaps in their data 
coverage (25,908) 
Patients with gender recorded as “indeterminate” (2) 
Patients without a record indicating a UTI (645,976) 
Rheumatoid arthritis 2140 (2.8) 803 (3.0) 339 (3.1) 97 (3.6) 9 (2.6) 
Cancer 11291 (14.8) 4211 (15.6) 1891 (17.4) 498 (18.7) 82 (24.0) 
Stroke 6714 (8.8) 3123 (11.6) 1695 (15.6) 454 (17.0) 67 (19.6) 
Diabetes 11956 (15.7) 5103 (18.9) 2863 (26.4) 961 (36.0) 112 (32.7) 
Liver disease 445 (0.6) 165 (0.6) 69 (0.6) 11 (0.4) 3 (0.9) 
Ischaemic heart disease 11611 (15.3) 5814 (21.6) 3118 (28.7) 878 (32.9) 114 (33.3) 
Urinary catheter 2360 (3.1) 854 (3.2) 504 (4.6) 193 (7.2) 39 (11.4) 
Urinary incontinence 10966 (14.4) 4089 (15.2) 1702 (15.7) 398 (14.9) 41 (12.0) 
Polypharmacy 24478 (32.2) 11419 (42.3) 6371 (58.7) 1797 (67.4) 237 (69.3) 
Potassium-sparing diuretic  1470 (1.9) 946 (3.5) 732 (6.7) 158 (5.9) 4 (1.2) 
Angiotensin-converting enzyme 
inhibitor 
16430 (21.6) 7586 (28.1) 3446 (31.7) 718 (26.9) 46 (13.5) 
Angiotensin-II receptor antagonist 8195 (10.8) 3933 (14.6) 1885 (17.4) 453 (17.0) 42 (12.3) 
Charlson score 
0 
1 
2 
3 
4 
5 
≥6 
 
30663 (40.3) 
18770 (24.7) 
12973 (17.0) 
7394 (9.7) 
3219 (4.2) 
1636 (2.1) 
1457 (1.9) 
 
6131 (22.7) 
4100 (15.2) 
6309 (23.4) 
4666 (17.3) 
2725 (10.1) 
1661 (6.2) 
1378 (5.1) 
 
879 (8.1) 
824 (7.6) 
2621 (24.1) 
2424 (22.3) 
1728 (15.9) 
1148 (10.6) 
1230 (11.3) 
 
104 (3.9) 
116 (4.3) 
504 (18.9) 
577 (21.6) 
481 (18.0) 
401 (15.0) 
484 (18.1) 
 
6 (1.8) 
12 (3.5) 
81 (23.7) 
64 (18.7) 
66 (19.3) 
45 (13.2) 
68 (19.9) 
Numbers are values (%) unless otherwise stated. 
 
Outcomes according to calculated eGFR 
There were 7203 re-consultations with urinary symptoms resulting in another antibiotic 
prescription within 14 days of the incident UTIs, equating to about 6% of the cohort. 
The odds of re-consulting and receiving another antibiotic prescription were no 
different between those with an eGFR ≥60mls/min/1.73m2 and those with 
eGFRs<60mls/min/1.73m2 (Table 2). 
Table 2. Adjusted odds ratios and 95% confidence intervals for each outcome by eGFR category. 
Re-consultation and re-prescription within 14 days Number of UTIs Number (%) of events crude OR Adjusted* OR (95% CI) p-value 
eGFR ≥60 76112 4852 (6.4) 1 1  
eGFR 45-59 26970 1563 (5.8) 0.90 0.97 (0.91-1.03) 0.328 
eGFR 30-44 10854 626 (5.8) 0.90 1.03 (0.94-1.14) 0.511 
eGFR 15-29 2667 148 (5.5) 0.86 1.02 (0.86-1.22) 0.804 
eGFR <15 342 14 (4.1) 0.63 0.72 (0.42-1.23) 0.224 
Hospitalised for UTI within 14 days  
    
eGFR ≥60 76112 1003 (1.3) 1 1  
eGFR 45-59 26970 526 (2.0) 1.49 1.14 (1.01-1.28) 0.028 
eGFR 30-44 10854 317 (2.9) 2.25 1.25 (1.08 - 1.44) 0.003 
eGFR 15-29 2667 129 (4.8) 3.81 1.76 (1.43-2.16) <0.001 
eGFR <15 342 16 (4.7) 3.68 1.68 (1.01 -2.82) <0.001 
Hospitalised for sepsis within 14 days  
    
eGFR ≥60 76112 77 (0.1) 1 1  
eGFR 45-59 26970 46 (0.2) 1.69 1.36 (0.92-2.01) 0.119 
eGFR 30-44 10854 32 (0.3) 2.92 1.70 (1.06-2.72) 0.027 
eGFR 15-29 2667 17 (0.6) 6.33 2.72 (1.50-4.94) <0.001 
eGFR <15 342 4 (1.2) 11.69 4.24 (1.48-11.23) 0.007 
Hospitalised for AKI within 14 days  
    
eGFR ≥60 76112 280 (0.4) 1 1  
eGFR 45-59 26970 204 (0.8) 2.06 1.57 (1.29-1.91) <0.001 
eGFR 30-44 10854 231 (2.1) 5.89 3.21 (2.61-3.94) <0.001 
eGFR 15-29 2667 137 (5.1) 14.67 6.70 (5.24-8.55) <0.001 
eGFR <15 342 13 (3.8) 10.70 4.53 (2.52-8.17) <0.001 
Death within 28 days  
    
eGFR ≥60 76112 588 (0.8) 1 1  
eGFR 45-59 26970 285 (1.1) 1.37 0.92 (0.79-1.07) 0.275 
eGFR 30-44 10854 201 (1.9) 2.42 1.05 (0.87-1.26) 0.598 
eGFR 15-29 2667 99 (3.7) 4.95 1.63 (1.27-2.10) <0.001 
eGFR <15 342 19 (5.6) 7.56 2.37 (1.44-3.89) <0.001 
*Odds ratios adjusted for age, gender, Index of Multiple Deprivation score quintile, Charlson comorbidity score, being housebound, respiratory disease, 
peripheral vascular disease, liver disease, rheumatoid arthritis, diabetes, dementia, coronary heart disease, stroke, cancer, heart failure, polypharmacy, long-
term prescribing of angiotensin-converting enzyme inhibitors, angiotensin-II receptor blockers, or potassium-sparing diuretics, urinary catheter, urinary 
incontinence and choice and duration of antibiotic therapy  
 
There were 1991 hospitalisations for UTI (1.7% of the cohort), 176 for sepsis (0.2% of 
the cohort) and 865 for AKI (0.7% of the cohort), within 14 days of the incident UTIs. 
Compared to those with an eGFR ≥60mls/min/1.73m2, odds of hospitalisation for UTI 
increased in those with eGFRs of 45-59 (adjusted OR 1.14, 95% CI 1.01-1.28), 30-44 
(adjusted OR 1.25, 95% CI 1.08-1.44), 15-29 (adjusted OR 1.76, 95% CI 1.43-2.16), 
and <15 (adjusted OR 1.68, 95% CI 1.01-2.82). Odds of hospitalisation for sepsis were 
no different in those with an eGFR of 45-59, but were significantly higher in those with 
eGFRs of 30-44 (adjusted OR 1.70, 95% CI 1.06-2.72), 15-29 (adjusted OR 2.72, 95% 
CI 1.50-4.94), and <15 (adjusted OR 4.24, 95% CI 1.48-11.23). The risk of 
hospitalisation for AKI increased in a graded manner relative to renal function, with 
adjusted ORs of 1.57 (95% CI 1.29 – 1.91), 3.21 (95% CI 2.61 – 3.94), 6.70 (95% CI 
5.24 – 8.55), and 4.53 (95% CI 2.52 - 8.17) for eGFRs of 45-59, 30-44, 15-29 and <15 
mls/min/1.73m2 respectively. 
There were 1162 deaths in the 28 days following the incident UTIs, equating to about 
1% of the cohort. Compared to those with an eGFR ≥60mls/min/1.73m2, the odds of 
death were no different in those with an eGFR ≥30mls/min/1.73m2, 63% higher in 
those with an eGFR of 15-29 (adjusted OR 1.63, 95% CI 1.27-2.10), and over two-fold 
higher in those with an eGFR <15 (adjusted OR 2.37, 95% CI 1.44-3.89). 
Trimethoprim versus nitrofurantoin in those with an eGFR 
<60mls/min/1.73m2 
Of the 40,833 patients with an eGFR <60mls/min/1.73m2, 24,471 (60%) were 
prescribed trimethoprim and 7484 (18%) were prescribed nitrofurantoin. We matched 
20,948 patients with an eGFR of 45-60 (15,711 prescribed trimethoprim, 5237 
prescribed nitrofurantoin), 7260 with an eGFR of 30-44 (5445 prescribed trimethoprim, 
1815 prescribed nitrofurantoin), and 1728 with an eGFR <30 (1296 prescribed 
trimethoprim, 432 prescribed nitrofurantoin). Inspection of jitter plots and histograms 
suggested matching had improved balance of covariates across trimethoprim versus 
nitrofurantoin groups. Standardised mean differences were all less than 0.1 (Table 3).   
 
Table 3. Balance of baseline characteristics across trimethoprim and nitrofurantoin 
groups following propensity score matching for patients with renal impairment.  
eGFR 45-60mls/min/1.73m2 Trimethoprim Nitrofurantoin Standardised mean difference 
N 15711 5237  
Men 3421 (21.8) 1120 (21.4) 0.01 
Mean (SD) age 78.9 (8.3) 78.8 (8.2) -0.02 
Index of multiple deprivation decile 
1 or 2 (least deprived) 
3 or 4 
5 or 6 
7 or 8 
9 or 10 (most deprived) 
 
3746 (23.8) 
3807 (24.2) 
3488 (22.2) 
2711 (17.3) 
1959 (12.5) 
 
1305 (24.9) 
1257 (24.0) 
1088 (20.8) 
867 (16.6) 
720 (13.7) 
 
 
 
 
 
0.00 
Housebound 637 (4.1) 206 (3.9) -0.01 
Respiratory disease 3173 (20.2) 1115 (21.3) 0.00 
Cardiac failure 952 (6.1) 317 (6.1) 0.00 
Dementia 1111 (7.1) 361 (6.9) -0.01 
Cancer 2389 (15.2) 853 (16.3) 0.03 
Stroke 1768 (11.3) 611 (11.7) 0.01 
Diabetes 2890 (18.4) 956 (18.3) 0.00 
Ischaemic heart disease 3244 (20.6) 1098 (21) 0.01 
Urinary catheter 406 (2.6) 176 (3.4) 0.00 
Urinary incontinence 2337 (14.9) 883 (16.9) 0.05 
Polypharmacy 6497 (41.4) 2262 (43.2) 0.04 
Potassium-sparing diuretic  551 (3.5) 197 (3.8) 0.01 
Angiotensin-converting enzyme inhibitor 4364 (27.8) 1437 (27.4) -0.01 
Angiotensin-II receptor antagonist 2294 (14.6) 786 (15) 0.01 
Charlson score 
0 
1 
2 
3 
4 
5 
≥6 
 
3802 (24.2) 
2426 (15.4) 
3669 (23.4) 
2632 (16.8) 
1561 (9.9) 
891 (5.7) 
730 (4.6) 
 
1212 (23.1) 
814 (15.5) 
1256 (24) 
904 (17.3) 
490 (9.4) 
313 (6.0) 
248 (4.7) 
 
 
 
 
 
 
 
0.02 
 
eGFR 30-44mls/min/1.73m2 Trimethoprim Nitrofurantoin Standardised mean difference 
N 5445 1815  
Men 1201 (22.1) 414 (22.8) -0.02 
Mean (SD) age 82.3 (7.9) 82.2 (8.0) -0.01 
Index of multiple deprivation decile 
1 or 2 (least deprived) 
3 or 4 
5 or 6 
7 or 8 
9 or 10 (most deprived) 
 
1162 (21.3) 
1219 (22.4) 
1229 (22.6) 
986 (18.1) 
849 (15.6) 
 
360 (19.8) 
466 (25.7) 
394 (21.7) 
301 (16.6) 
294 (16.2) 
 
 
 
 
 
0.00 
Housebound 475 (8.7) 167 (9.2) 0.02 
Respiratory disease 1148 (21.1) 384 (21.2) 0.00 
Cardiac failure 657 (12.1) 226 (12.5) 0.01 
Dementia 605 (11.1) 201 (11.1) 0.00 
Cancer 924 (17) 314 (17.3) 0.01 
Stroke 880 (16.2) 304 (16.7) 0.02 
Diabetes 1493 (27.4) 527 (29) 0.04 
Ischaemic heart disease 1517 (27.9) 503 (27.7) 0.00 
Urinary catheter 240 (4.4) 112 (6.2) 0.07 
Urinary incontinence 882 (16.2) 302 (16.6) 0.01 
Polypharmacy 3302 (60.6) 1117 (61.5) 0.02 
Potassium-sparing diuretic  391 (7.2) 137 (7.5) 0.01 
Angiotensin-converting enzyme inhibitor 1758 (32.3) 593 (32.7) 0.01 
Angiotensin-II receptor antagonist 941 (17.3) 307 (16.9) -0.01 
Charlson score 
0 
1 
2 
3 
4 
5 
≥6 
 
441 (8.1) 
441 (8.1) 
1283 (23.6) 
1237 (22.7) 
894 (16.4) 
550 (10.1) 
599 (11.0) 
 
147 (8.1) 
144 (7.9) 
442 (24.4) 
381 (21.0) 
273 (15.0) 
213 (11.7) 
215 (11.8) 
 
 
 
 
 
 
 
0.02 
 
eGFR <30mls/min/1.73m2 Trimethoprim Nitrofurantoin Standardised mean difference 
N 1296 432  
Men 339 (26.2) 113 (26.2) 0.00 
Mean (SD) age 83.4 (8.2) 83.4 (8.0) 0.00 
Index of multiple deprivation decile 
1 or 2 (least deprived) 
3 or 4 
5 or 6 
7 or 8 
9 or 10 (most deprived) 
 
281 (21.7) 
297 (22.9) 
286 (22.1) 
231 (17.8) 
201 (15.5) 
 
93 (21.5) 
95 (22.0) 
100 (23.1) 
79 (18.3) 
65 (15.0) 
 
 
 
 
 
0.02 
Housebound 131 (10.1) 42 (9.7) -0.01 
Respiratory disease 250 (19.3) 86 (19.9) 0.02 
Cardiac failure 224 (17.3) 71 (16.4) -0.02 
Dementia 132 (10.2) 42 (9.7) -0.02 
Cancer 229 (17.7) 74 (17.1) -0.01 
Stroke 215 (16.6) 71 (16.4) 0.00 
Diabetes 451 (34.8) 155 (35.9) 0.02 
Ischaemic heart disease 406 (31.3) 132 (30.6) -0.02 
Urinary catheter 93 (7.2) 29 (6.7) -0.02 
Urinary incontinence 193 (14.9) 63 (14.6) -0.01 
Polypharmacy 877 (67.7) 294 (68.1) 0.01 
Potassium-sparing diuretic  76 (5.9) 23 (5.3) -0.02 
Angiotensin-converting enzyme inhibitor 340 (26.2) 112 (25.9) -0.01 
Angiotensin-II receptor antagonist 220 (17.0) 79 (18.3) 0.03 
Charlson score 
0 
1 
2 
3 
4 
5 
≥6 
 
51 (3.9) 
57 (4.4) 
291 (22.5) 
276 (21.3) 
229 (17.7) 
179 (13.8) 
213 (16.4) 
 
21 (4.9) 
21 (4.9) 
92 (21.3) 
93 (21.5) 
79 (18.3) 
56 (13.0) 
70 (16.2) 
 
 
 
 
 
 
 
-0.03 
Numbers are values (%) unless otherwise stated. 
 
Empirical nitrofurantoin prescribing was associated with lower odds of hospitalisation 
for AKI across all eGFR groups (eGFR 45-59: OR 0.62, 95% CI 0.40-0.94; eGFR 30-
44: OR 0.47, 95% CI 0.30-0.73; eGFR <30: OR 0.45, 95% CI 0.25-0.81) (Table 4). 
Nitrofurantoin was also associated with lower odds of re-consultation and re-
prescription in patients with eGFRs of 45-59 (OR 0.74, 95% CI 0.61-0.91) and lower 
odds of death in patients with eGFRs of 30-44 (OR 0.61, 95% CI 0.39-0.95). There 
were no other statistically significant differences between empirical trimethoprim 
versus nitrofurantoin prescribing. Importantly, we did not detect any increase in odds 
of adverse outcomes in patients prescribed nitrofurantoin.
Table 4. Odds ratios and 95% confidence intervals for each outcome in propensity-score* matched trimethoprim versus nitrofurantoin 
groups, across three eGFR categories. 
eGFR 45-59 Trimethoprim group, n=15711 Nitrofurantoin group, n=5237  
 
 
Number (%) of events Number (%) of events  OR (95% CI) p-value 
Death within 28 days 159 (1.0) 50 (1.0) 0.94 (0.69-1.30) 0.718 
Re-consultation and re-prescription within 14 days 942 (6.0) 290 (5.5) 0.74 (0.61-0.91) 0.004 
Hospitalised for UTI within 14 days 288 (1.8) 105 (2.0) 1.09 (0.74-1.61) 0.648 
Hospitalised for sepsis within 14 days 25 (0.2) 6 (0.72) 0.72 (0.30-1.76) 0.470 
Hospitalised for AKI within 14 days 126 (0.8) 26 (0.5) 0.62 (0.40-0.94) 0.025 
     
eGFR 30-44 Trimethoprim group, n=5445 Nitrofurantoin group, n=1815  
 
 
Number (%) of events Number (%) of events  OR (95% CI) p-value 
Death within 28 days 113 (2.1) 23 (1.3) 0.61 (0.39-0.95) <0.001 
Re-consultation and re-prescription within 14 days 318 (5.8) 117 (6.4) 0.98 (0.71-1.33) 0.874 
Hospitalised for UTI within 14 days 168 (3.1) 57 (3.1) 0.80 (0.44-1.47) 0.482 
Hospitalised for sepsis within 14 days 14 (0.3) 2 (0.1) 0.43 (0.10-1.88) 0.262 
Hospitalised for AKI within 14 days 146 (2.7) 23 (1.3) 0.47 (0.30-0.73) <0.001 
     
eGFR <30 Trimethoprim group, n=1296 Nitrofurantoin group, n=432  
 
 
Number (%) of events Number (%) of events  OR (95% CI) p-value 
Death within 28 days 49 (3.8) 18 (4.2) 1.11(0.64-1.93) 0.713 
Re-consultation and re-prescription within 14 days 74 (5.7) 29 (6.7) 1.19 (0.76-1.85) 0.446 
Hospitalised for UTI within 14 days 73 (5.6) 23 (5.3) 0.94 (0.58-1.53) 0.808 
Hospitalised for sepsis within 14 days 8 (0.6) 2 (0.5) 0.75 (0.16-3.54) 0.715 
Hospitalised for AKI within 14 days 84 (6.5) 13 (3.0) 0.45 (0.25-0.81) 0.008 
 
*The following baseline variables were used in the propensity-score model: age, gender, Index of Multiple Deprivation score quintile, Charlson 
comorbidity score, being housebound, the presence or absence of respiratory disease, peripheral vascular disease, liver disease, rheumatoid arthritis, 
diabetes, dementia, coronary heart disease, stroke, cancer, heart failure, urinary catheter, urinary incontinence, polypharmacy, long-term prescribing of 
angiotensin-converting enzyme inhibitors, angiotensin-II receptor blockers, or potassium-sparing diuretics.
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Sensitivity analyses 
We restricted our eGFR and outcomes analysis to patients with a creatinine measured 
in the 90 days prior to the incident UTI, to increase the likelihood that the calculated 
eGFR reflected their current renal function. Results were consistent with our main 
analysis and most of the statistically significant odds ratios increased in magnitude (S1 
Table). We also combined the hospitalisation and death outcomes in our trimethoprim 
versus nitrofurantoin analysis to increase statistical power to detect these adverse 
outcomes (S2 Table). Findings were consistent with our main analysis. 
 
Discussion 
Our results show that compared to an eGFR of >60mls/min/1.73m2, older patients with 
an eGFR of <60mls/min/1.73m2, who were empirically treated for suspected UTI in 
primary care, had greater odds of hospitalisation for UTI and AKI, those with an eGFR 
<45 had greater odds of hospitalisation for sepsis, and those with an eGFR <30 had 
greater odds of death. The magnitude of each association generally increased relative 
to the severity of the renal impairment. We also showed that compared to 
trimethoprim, nitrofurantoin was associated with reduced odds of hospitalisation for 
AKI across all eGFR groups, and was not associated with an increased risk of any 
adverse event evaluated in our study.   
Results in context 
Previous research focussed on the risk of infection-related hospitalisation in adults 
with renal impairment and showed a greater risk of hospitalisation for pneumonia, UTI, 
bacteraemia and cellulitis in those with eGFRs<60mls/min/1.73m2[4-6]. Previous 
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studies also showed a greater risk of death following an infection-related 
hospitalisation in patients with renal impairment[3-5], but provided little information on 
health service contact prior to the adverse outcome, thus limiting interpretation about 
possible opportunities to intervene. Our study shows an increased risk of infection-
related hospitalisation and death in older adults with renal impairment, following 
infection-related presentation and treatment in primary care. We also show increased 
odds of AKI hospitalisation in those with lower initial eGFRs, previously only 
investigated in a small cohort (n=790) of patients hospitalised with UTI, who likely had 
more severe infection on initial presentation[26]. To the best of our knowledge, this is 
the first study to investigate the impact of eGFR on odds of re-consultation and re-
prescription following an infection-related illness. We found no difference in the odds 
of this outcome across the different eGFR groups, suggesting the increased odds of 
UTI, sepsis and death were less likely to be due to treatment non-response and more 
likely to be related to other patient or renal factors.  
Trimethoprim (with or without sulfamethoxazole) prescribing is associated with an 
increased risk of hyperkalaemia, AKI and death, compared to amoxicillin[16-19]. 
Amoxicillin accounts for only about 5% of prescribing for UTI in the UK [9] and thus, is 
a less helpful comparator for clinical decision-making. Furthermore, these studies did 
not investigate associations by degree of renal impairment, providing little information 
to guide prescribing in this population. Two studies assessed trimethoprim and 
nitrofurantoin prescribing in patients with renal impairment. The first compared 
treatment failure rates in women with UTI prescribed nitrofurantoin according to renal 
function and found no difference across the eGFR groups[14]. This study lacked a 
comparator group prescribed an alternative antibiotic, which makes it difficult to 
interpret their findings. The second compared outcomes in older women with a median 
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eGFR of 38mls/min/1.73m2, prescribed either nitrofurantoin or trimethoprim, and found 
no difference in risk of treatment failure or UTI hospitalisation[27]. We compared 
nitrofurantoin with trimethoprim across three eGFR groups, and found that 
nitrofurantoin was associated with lower odds of re-consultation and re-prescription in 
patients with eGFRs of 45-59. This could be explained by recent data showing that 
34% of community-acquired E.coli UTIs in England are resistant to trimethoprim, 
compared to only 2.7% resistant to nitrofurantoin[28].  We did not find statistically 
significant differences between re-consultation and re-prescription rates in people with 
eGFRs <45. This could be due to less statistical power, as nitrofurantoin use was less 
common in these patients due to the advice to use with care in patients with eGFRs 
of 30-44 and to avoid in eGFRs <30. It may also be due to the possibility that 
nitrofurantoin efficacy was reduced in those with lower eGFRs but was offset by the 
high rates of trimethoprim resistance and thus resulted in apparent similar rates of re-
consultation and re-prescription. Our finding that nitrofurantoin was associated with a 
reduced risk of death in those with moderate renal impairment is consistent with  
previously reported estimates in studies that compared nitrofurantoin with amoxicillin 
in the general population[18,19]. We also found a previously unreported lower risk of 
AKI associated with nitrofurantoin use across all three eGFR groups of our cohort.    
Strengths and weaknesses of this study 
We used data from a general practice database that is broadly representative of the 
UK population, increasing the generalisability of our findings. This is the largest cohort 
study to investigate the impact of eGFR on infection-related outcomes, with a sample 
size >4 times larger than the previously largest study[4]. Cohort entry was dependent 
on presentation and empirical treatment of UTI in primary care, and thus reduced 
indication bias. We adjusted for the presence/absence of more co-morbidities than 
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previous studies, increasing the likelihood of an independent association between 
eGFR and adverse outcomes. This is the first study to investigate trimethoprim versus 
nitrofurantoin prescribing in renal impairment, using clinically relevant eGFR groups 
analogous to stages of CKD, and without excluding men. We also reduced indication 
bias by matching patients on their propensity to receive trimethoprim, and achieving 
adequate balance of covariates across the two groups.  
Our study has important limitations. We attempted to capture patients presenting with 
UTI but had no microbiological data to support this. However, whilst a limitation, this 
is also more representative of clinical practice. We were unable to investigate 
pulmonary/hepatic toxicity related to nitrofurantoin use due to the lack of reliable 
codes, and differential use of these codes by clinicians. However, two systematic 
reviews have shown that these toxicities are rare with short-term use[29,30]. We relied 
on a creatinine measurement from the 24 months prior to the UTI to estimate an eGFR, 
but this may not fully represent patients’ current renal function. Finally, despite our 
design, differential coding, indication bias and residual confounding may still have 
affected our findings. 
Clinical implications 
Around 20% of adults aged ≥65 present to primary care at least once with a UTI [9] 
and around 20% have renal impairment [2] and thus, are at greater risk of an adverse 
outcome. The initial primary care visit presents a potential opportunity to address this 
increased risk. However, recommended interventions such as stopping co-prescribed 
angiotensin-converting enzyme inhibitors or angiotensin-II receptor blockers have not 
been evaluated in the primary care setting[31]. Therefore, there is a need for research 
that evaluates primary care based interventions that may prevent adverse outcomes, 
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including AKI, in patients with renal impairment and community acquired infection. The 
absolute risks of hospitalisation and death are low. Therefore, interventions may be 
best targeted at those at highest risk – i.e. those with more severe renal impairment.   
Current guidelines and the British National Formulary limit nitrofurantoin use to those 
with an eGFR >45mls/min/1.73m2, although short courses can be used with care in 
those with eGFRs >30mls/min/1.73m2[11]. We found no evidence to support this 
limitation, and actually found nitrofurantoin to be associated with a reduced risk of AKI 
compared to trimethoprim. Research suggesting poorer nitrofurantoin efficacy in 
patients with renal impairment assessed urinary nitrofurantoin excretion, not clinical 
outcomes, and was restricted to small samples[13]. Our findings, combined with 
increasing rates of bacterial resistance to trimethoprim, and the importance of avoiding 
broader spectrum agents, support wider use of nitrofurantoin for older patients with 
low eGFRs.  
Conclusion 
Our findings show that older patients with renal impairment presenting to primary care 
with a UTI are at greater risk of adverse outcomes independent of other co-morbidities 
and of prescribed empirical antibiotic treatment. Despite documented concerns, we 
found no increased risk of adverse outcomes in patients with an eGFR 
<60mls/min/1.73m2 prescribed nitrofurantoin and support its wider use in selected 
patients with moderate-severe renal impairment.  
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